FILTER
Clear Filter
AUDIT TRAIL
SNo. User Input time Data Source Drug Event Actual Narrative Edited Narative
1 911940 2022-03-22 10:47:52 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 977 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
2 911940 2022-03-22 10:59:29 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 977 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 977 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Total Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis.
3 911940 2022-03-22 11:09:54 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 977 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 977 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Total. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis.
4 911940 2022-03-22 18:12:24 CAERS COSENTYX No event selected No aggregated narrative No changes made
5 911940 2022-03-22 18:12:52 FAERS COSENTYX No event selected No aggregated narrative No changes made
6 911940 2022-03-22 18:13:58 CAERS COSENTYX No event selected No aggregated narrative No changes made
7 911940 2022-03-22 18:14:51 CAERS COSENTYX No event selected No aggregated narrative No changes made
8 911940 2022-03-22 18:16:09 FAERS COSENTYX No event selected No aggregated narrative No changes made
9 911940 2022-03-22 18:16:28 FAERS COSENTYX No event selected No aggregated narrative No changes made
10 911940 2022-03-22 18:16:48 FAERS COSENTYX No event selected No aggregated narrative No changes made
11 911940 2022-03-22 18:17:12 CAERS COSENTYX No event selected No aggregated narrative No changes made
12 911940 2022-03-22 18:45:25 CAERS COSENTYX No event selected No aggregated narrative No changes made
13 911940 2022-03-22 18:51:26 CAERS COSENTYX No event selected No aggregated narrative No changes made
14 911940 2022-03-22 18:56:26 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 0 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
15 911940 2022-03-22 19:32:20 CAERS COSENTYX No event selected No aggregated narrative No changes made
16 911940 2022-03-22 19:33:26 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 977 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
17 911940 2022-03-22 19:34:06 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
18 911940 2022-03-22 19:34:37 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
19 911940 2022-03-22 19:40:23 FAERS COSENTYX No event selected No aggregated narrative No changes made
20 911940 2022-03-22 19:40:58 CAERS COSENTYX Psoriasis There were a total of 292 cases reported for COSENTYX with Psoriasis for the review period May-2021 to Aug-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
21 911940 2022-03-22 19:41:53 CAERS COSENTYX Psoriasis There were a total of 292 cases reported for COSENTYX with Psoriasis for the review period May-2021 to Aug-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
22 911940 2022-03-22 19:42:54 CAERS COSENTYX Psoriasis There were a total of 292 cases reported for COSENTYX with Psoriasis for the review period May-2021 to Aug-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
23 911940 2022-03-22 19:47:55 CAERS COSENTYX Psoriasis There were a total of 292 cases reported for COSENTYX with Psoriasis for the review period May-2021 to Aug-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
24 911940 2022-03-22 19:49:42 CAERS COSENTYX Psoriasis There were a total of 292 cases reported for COSENTYX with Psoriasis for the review period May-2021 to Aug-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
25 911940 2022-03-22 20:47:49 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
26 911940 2022-03-22 20:49:31 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
27 911940 2022-03-22 20:54:14 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
28 911940 2022-03-22 20:55:18 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
29 911940 2022-03-22 20:56:20 CAERS COSENTYX No event selected No aggregated narrative No changes made
30 911940 2022-03-22 20:56:34 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
31 911940 2022-03-22 20:58:34 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
32 911940 2022-03-22 20:59:37 FAERS COSENTYX Drug ineffective There were a total of 942 cases reported for COSENTYX with Drug ineffective for the review period May-2021 to Aug-2021. Of the 942 number of cases, 700 cases were reported from the country US, 130 cases were reported from CA, 58 cases were reported from BR, 12 cases were reported from GB, 11 cases were reported from AR. The information on confounding factor time-to-onset is available in 240 cases. Concomitant medication(s) have been reported for 1,073 cases. Of the 942 cases, Information on Dechallenge is available in 73 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Drug ineffective. No changes made
33 911940 2022-03-22 21:00:31 FAERS COSENTYX Drug ineffective There were a total of 1,148 cases reported for COSENTYX with Drug ineffective for the review period Sep-2021 to Dec-2021. Of the 1,148 number of cases, 936 cases were reported from the country US, 104 cases were reported from CA, 54 cases were reported from BR, 13 cases were reported from AR, 12 cases were reported from EG. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 1,087 cases. Of the 1,148 cases, Information on Dechallenge is available in 82 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Drug ineffective. No changes made
34 911940 2022-03-22 21:01:25 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 977 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
35 911940 2022-03-22 21:10:53 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
36 911940 2022-03-22 21:11:05 CAERS COSENTYX Psoriasis There were a total of 292 cases reported for COSENTYX with Psoriasis for the review period May-2021 to Aug-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
37 911940 2022-03-22 21:14:00 CAERS COSENTYX Psoriasis There were a total of 292 cases reported for COSENTYX with Psoriasis for the review period May-2021 to Aug-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
38 911940 2022-03-22 21:14:44 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
39 911940 2022-03-22 21:24:18 FAERS COSENTYX Psoriasis There were a total of 1,179 cases reported for COSENTYX with Psoriasis for the review period May-2021 to Aug-2021. Of the 1,179 number of cases, 877 cases were reported from the country US, 114 cases were reported from CA, 90 cases were reported from BR, 32 cases were reported from AR, 11 cases were reported from EG. The information on confounding factor time-to-onset is available in 348 cases. Concomitant medication(s) have been reported for 948 cases. Of the 1,179 cases, Information on Dechallenge is available in 82 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
40 911940 2022-03-22 21:25:25 FAERS COSENTYX No event selected No aggregated narrative No changes made
41 911940 2022-03-22 21:25:44 FAERS COSENTYX No event selected No aggregated narrative No changes made
42 911940 2022-03-22 21:26:03 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
43 911940 2022-03-22 21:26:52 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
44 911940 2022-03-22 21:27:34 CAERS COSENTYX Psoriasis There were a total of 292 cases reported for COSENTYX with Psoriasis for the review period May-2021 to Aug-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
45 911940 2022-03-22 21:42:31 FAERS COSENTYX Drug ineffective There were a total of 942 cases reported for COSENTYX with Drug ineffective for the review period May-2021 to Aug-2021. Of the 942 number of cases, 700 cases were reported from the country US, 130 cases were reported from CA, 58 cases were reported from BR, 12 cases were reported from GB, 11 cases were reported from AR. The information on confounding factor time-to-onset is available in 240 cases. Concomitant medication(s) have been reported for 1,073 cases. Of the 942 cases, Information on Dechallenge is available in 73 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Drug ineffective. No changes made
46 911940 2022-03-22 21:44:25 FAERS COSENTYX No event selected No aggregated narrative No changes made
47 911940 2022-03-22 21:44:59 CAERS COSENTYX No event selected No aggregated narrative No changes made
48 911940 2022-03-22 21:52:23 FAERS COSENTYX No event selected No aggregated narrative No changes made
49 911940 2022-03-22 21:53:13 CAERS COSENTYX Drug ineffective There were a total of 387 cases reported for COSENTYX with Drug ineffective for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Drug ineffective. No changes made
50 911940 2022-03-22 21:54:26 CAERS COSENTYX Psoriasis There were a total of 292 cases reported for COSENTYX with Psoriasis for the review period May-2021 to Aug-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
51 911940 2022-03-22 21:55:19 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
52 911940 2022-03-22 22:04:07 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 977 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
53 911940 2022-03-22 22:32:49 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
54 911940 2022-03-22 22:42:59 COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made nan
55 911940 2022-03-22 22:46:30 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 977 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
56 911940 2022-03-22 22:47:22 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
57 911940 2022-03-22 23:11:27 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 1 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
58 911940 2022-03-22 23:17:03 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 977 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
59 911940 2022-03-22 23:28:41 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 234 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
60 911940 2022-03-22 23:32:50 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 977 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
61 911940 2022-03-22 23:36:08 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 234 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
62 911940 2022-03-22 23:51:13 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 234 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
63 911940 2022-03-23 00:22:38 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 234 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
64 911940 2022-03-23 00:35:39 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 234 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
65 911940 2022-03-23 00:58:28 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 234 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
66 911940 2022-03-23 13:05:29 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 234 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
67 911940 2022-03-23 13:10:34 CAERS COSENTYX No event selected No aggregated narrative No changes made
68 911940 2022-03-23 13:17:42 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 234 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
69 911940 2022-03-23 13:25:17 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 0 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
70 911940 2022-03-23 13:47:54 FAERS COSENTYX No event selected No aggregated narrative No changes made
71 911940 2022-03-23 14:02:01 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
72 911940 2022-03-23 14:04:03 CAERS COSENTYX Psoriasis There were a total of 292 cases reported for COSENTYX with Psoriasis for the review period May-2021 to Aug-2021.Concomitant medication(s) have been reported for 273 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
73 911940 2022-03-23 14:23:02 FAERS COSENTYX No event selected No aggregated narrative No changes made
74 911940 2022-03-23 14:23:47 CAERS COSENTYX Psoriasis There were a total of 292 cases reported for COSENTYX with Psoriasis for the review period May-2021 to Aug-2021.Concomitant medication(s) have been reported for 273 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
75 911940 2022-03-23 14:30:30 FAERS COSENTYX No event selected No aggregated narrative No changes made
76 911940 2022-03-23 14:31:01 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 199 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
77 911940 2022-03-23 15:00:59 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 199 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
78 911940 2022-03-23 15:14:14 CAERS COSENTYX Drug ineffective There were a total of 387 cases reported for COSENTYX with Drug ineffective for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 360 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Drug ineffective. No changes made
79 911940 2022-03-24 23:46:41 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
80 911940 2022-03-24 23:50:09 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
81 911940 2022-03-24 23:53:49 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 199 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
82 911940 2022-03-25 00:02:38 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
83 911940 2022-03-25 00:09:10 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 199 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
84 911940 2022-03-25 00:23:10 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
85 911940 2022-03-25 00:30:20 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 199 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
86 911940 2022-03-25 00:57:51 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 199 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
87 911940 2022-03-25 01:09:15 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 199 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
88 911940 2022-03-25 01:28:41 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 199 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
89 911940 2022-03-25 01:39:31 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 199 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
90 911940 2022-03-28 23:54:28 CAERS COSENTYX No event selected No aggregated narrative No changes made
91 911940 2022-03-28 23:55:01 FAERS COSENTYX No event selected No aggregated narrative No changes made
92 911940 2022-03-28 23:55:29 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 199 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
93 911940 2022-03-29 00:18:45 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 199 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 199 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. Yes
94 911940 2022-03-29 00:20:53 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. Yes
95 911940 2022-03-29 18:45:42 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
96 911940 2022-03-30 11:51:53 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 199 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
97 911940 2022-03-30 12:03:00 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. Yes ruled out
98 911940 2022-04-04 20:26:52 COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 199 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made nan
99 911940 2022-04-04 20:27:01 CAERS COSENTYX No event selected No aggregated narrative No changes made
100 911940 2022-04-04 20:27:25 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
101 911940 2022-04-04 20:28:33 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 199 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
102 911940 2022-04-04 20:28:49 CAERS COSENTYX No event selected No aggregated narrative No changes made
103 911940 2022-04-04 20:29:31 CAERS COSENTYX No event selected No aggregated narrative No changes made
104 911940 2022-04-25 12:14:20 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
105 911940 2022-04-25 14:33:08 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
106 911940 2022-04-25 14:36:06 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
107 911940 2022-04-25 15:11:10 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
108 911940 2022-04-25 15:20:08 FAERS COSENTYX Drug ineffective There were a total of 1,148 cases reported for COSENTYX with Drug ineffective for the review period Sep-2021 to Dec-2021. Of the 1,148 number of cases, 936 cases were reported from the country US, 104 cases were reported from CA, 54 cases were reported from BR, 13 cases were reported from AR, 12 cases were reported from EG. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 204 cases. Of the 1,148 cases, Information on Dechallenge is available in 82 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Drug ineffective. No changes made
109 911940 2022-04-25 15:51:21 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
110 911940 2022-04-25 16:00:09 FAERS COSENTYX Psoriasis There were a total of 1,179 cases reported for COSENTYX with Psoriasis for the review period May-2021 to Aug-2021. Of the 1,179 number of cases, 877 cases were reported from the country US, 114 cases were reported from CA, 90 cases were reported from BR, 32 cases were reported from AR, 11 cases were reported from EG. The information on confounding factor time-to-onset is available in 348 cases. Concomitant medication(s) have been reported for 216 cases. Of the 1,179 cases, Information on Dechallenge is available in 82 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
111 911940 2022-04-25 16:07:05 CAERS COSENTYX Psoriasis There were a total of 292 cases reported for COSENTYX with Psoriasis for the review period May-2021 to Aug-2021.Concomitant medication(s) have been reported for 273 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
112 911940 2022-04-25 16:07:50 FAERS COSENTYX Psoriasis There were a total of 1,179 cases reported for COSENTYX with Psoriasis for the review period May-2021 to Aug-2021. Of the 1,179 number of cases, 877 cases were reported from the country US, 114 cases were reported from CA, 90 cases were reported from BR, 32 cases were reported from AR, 11 cases were reported from EG. The information on confounding factor time-to-onset is available in 348 cases. Concomitant medication(s) have been reported for 216 cases. Of the 1,179 cases, Information on Dechallenge is available in 82 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
113 911940 2022-04-25 17:46:12 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
114 911940 2022-04-25 17:53:02 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
115 911940 2022-04-25 18:11:10 FAERS COSENTYX No event selected No aggregated narrative No changes made
116 911940 2022-04-25 18:11:18 FAERS COSENTYX No event selected No aggregated narrative No changes made
117 911940 2022-05-09 23:22:08 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
118 911940 2022-05-09 23:23:25 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 199 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
119 911940 2022-05-11 14:54:14 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
120 911940 2022-05-11 14:56:11 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 199 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
121 911940 2022-05-11 14:57:27 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
122 911940 2022-05-11 15:08:37 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
123 911940 2022-05-11 15:13:14 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 199 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
124 911940 2022-05-18 15:17:32 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
125 911940 2022-05-18 15:20:09 CAERS COSENTYX Psoriasis There were a total of 212 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 199 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
126 911940 2022-05-19 11:10:03 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
127 911940 2022-05-19 11:14:55 CAERS COSENTYX Drug ineffective There were a total of 387 cases reported for COSENTYX with Drug ineffective for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 360 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Drug ineffective. No changes made
128 911940 2022-05-19 15:09:18 FAERS COSENTYX Arthritis There were a total of 197 cases reported for COSENTYX with Arthritis for the review period Sep-2021 to Dec-2021. Of the 197 number of cases, 120 cases were reported from the country US, 28 cases were reported from CA, 20 cases were reported from BR, 8 cases were reported from AR, 6 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 60 cases. Of the 197 cases, Information on Dechallenge is available in 26 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Arthritis. No changes made
129 911940 2022-05-19 15:43:43 FAERS COSENTYX Ankylosing spondylitis There were a total of 97 cases reported for COSENTYX with Ankylosing spondylitis for the review period Sep-2021 to Dec-2021. Of the 97 number of cases, 38 cases were reported from the country CA, 24 cases were reported from US, 16 cases were reported from BR, 6 cases were reported from EG, 3 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 57 cases. Of the 97 cases, Information on Dechallenge is available in 19 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Ankylosing spondylitis. No changes made
130 911940 2022-05-19 15:49:25 FAERS COSENTYX Ankylosing spondylitis There were a total of 97 cases reported for COSENTYX with Ankylosing spondylitis for the review period Sep-2021 to Dec-2021. Of the 97 number of cases, 38 cases were reported from the country CA, 24 cases were reported from US, 16 cases were reported from BR, 6 cases were reported from EG, 3 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 57 cases. Of the 97 cases, Information on Dechallenge is available in 19 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Ankylosing spondylitis. No changes made
131 911940 2022-05-19 16:01:06 FAERS COSENTYX Ankylosing spondylitis There were a total of 97 cases reported for COSENTYX with Ankylosing spondylitis for the review period Sep-2021 to Dec-2021. Of the 97 number of cases, 38 cases were reported from the country CA, 24 cases were reported from US, 16 cases were reported from BR, 6 cases were reported from EG, 3 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 57 cases. Of the 97 cases, Information on Dechallenge is available in 19 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Ankylosing spondylitis. No changes made
132 911940 2022-05-19 16:16:21 FAERS COSENTYX Neck pain There were a total of 105 cases reported for COSENTYX with Neck pain for the review period Sep-2021 to Dec-2021. Of the 105 number of cases, 44 cases were reported from the country CA, 34 cases were reported from US, 20 cases were reported from BR, 2 cases were reported from AR, 2 cases were reported from EG. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 63 cases. Of the 105 cases, Information on Dechallenge is available in 18 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Neck pain. No changes made
133 911940 2022-05-19 17:25:42 FAERS COSENTYX No event selected No aggregated narrative No changes made
134 911940 2022-05-19 17:28:31 FAERS COSENTYX Drug ineffective There were a total of 1,148 cases reported for COSENTYX with Drug ineffective for the review period Sep-2021 to Dec-2021. Of the 1,148 number of cases, 936 cases were reported from the country US, 104 cases were reported from CA, 54 cases were reported from BR, 13 cases were reported from AR, 12 cases were reported from EG. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 204 cases. Of the 1,148 cases, Information on Dechallenge is available in 82 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Drug ineffective. No changes made
135 911940 2022-05-19 17:31:04 FAERS COSENTYX Pain There were a total of 841 cases reported for COSENTYX with Pain for the review period Sep-2021 to Dec-2021. Of the 841 number of cases, 506 cases were reported from the country US, 128 cases were reported from CA, 124 cases were reported from BR, 31 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 233 cases. Of the 841 cases, Information on Dechallenge is available in 88 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Pain. There were a total of 841 cases reported for COSENTYX with Pain for the review period Sep-2021 to Dec-2021. Of the 841 number of cases, 506 cases were reported from the country US, 128 cases were reported from CA, 124 cases were reported from BR, 31 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 233 cases. Of the 841 cases, Information on Dechallenge is available in 88 cases whereas no information on rechallenge is available.. Conclusion: Based on the available information, COSENTYX has been ruled out for event Pain.
136 911940 2022-05-19 17:45:41 FAERS COSENTYX No event selected No aggregated narrative No changes made
137 911940 2022-05-19 18:29:13 FAERS COSENTYX No event selected No aggregated narrative No changes made
138 911940 2022-05-19 18:31:37 FAERS COSENTYX Tuberculosis There were a total of 25 cases reported for COSENTYX with Tuberculosis for the review period Sep-2021 to Dec-2021. Of the 25 number of cases, 10 cases were reported from the country US, 8 cases were reported from BR, 3 cases were reported from CA, 2 cases were reported from AR, 2 cases were reported from CN. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 4 cases. Of the 25 cases, Information on Dechallenge is available in 4 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Tuberculosis. No changes made
139 911940 2022-05-19 19:20:15 FAERS COSENTYX No event selected No aggregated narrative No changes made
140 911940 2022-05-19 19:52:28 FAERS COSENTYX No event selected No aggregated narrative No changes made
141 911940 2022-05-19 20:11:48 FAERS COSENTYX Pigmentation disorder There were a total of 43 cases reported for COSENTYX with Pigmentation disorder for the review period Sep-2021 to Dec-2021. Of the 43 number of cases, 31 cases were reported from the country US, 5 cases were reported from BR, 3 cases were reported from AR, 2 cases were reported from CO, 1 cases were reported from CA. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 7 cases. Of the 43 cases, Information on Dechallenge is available in 3 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Pigmentation disorder. No changes made
142 911940 2022-05-20 18:27:48 FAERS COSENTYX Drug ineffective There were a total of 1,148 cases reported for COSENTYX with Drug ineffective for the review period Sep-2021 to Dec-2021. Of the 1,148 number of cases, 936 cases were reported from the country US, 104 cases were reported from CA, 54 cases were reported from BR, 13 cases were reported from AR, 12 cases were reported from EG. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 204 cases. Of the 1,148 cases, Information on Dechallenge is available in 82 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Drug ineffective. No changes made
143 911940 2022-05-23 13:52:16 FAERS COSENTYX Skin plaque There were a total of 129 cases reported for COSENTYX with Skin plaque for the review period Sep-2021 to Dec-2021. Of the 129 number of cases, 90 cases were reported from the country US, 19 cases were reported from CA, 9 cases were reported from CO, 4 cases were reported from AR, 4 cases were reported from BR. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 31 cases. Of the 129 cases, Information on Dechallenge is available in 12 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Skin plaque. No changes made
144 911940 2022-05-23 13:56:25 FAERS COSENTYX Pigmentation disorder There were a total of 43 cases reported for COSENTYX with Pigmentation disorder for the review period Sep-2021 to Dec-2021. Of the 43 number of cases, 31 cases were reported from the country US, 5 cases were reported from BR, 3 cases were reported from AR, 2 cases were reported from CO, 1 cases were reported from CA. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 7 cases. Of the 43 cases, Information on Dechallenge is available in 3 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Pigmentation disorder. No changes made
145 911940 2022-05-23 13:58:33 FAERS COSENTYX Drug ineffective There were a total of 1,148 cases reported for COSENTYX with Drug ineffective for the review period Sep-2021 to Dec-2021. Of the 1,148 number of cases, 936 cases were reported from the country US, 104 cases were reported from CA, 54 cases were reported from BR, 13 cases were reported from AR, 12 cases were reported from EG. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 204 cases. Of the 1,148 cases, Information on Dechallenge is available in 82 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Drug ineffective. No changes made
146 911940 2022-05-23 14:00:21 FAERS COSENTYX Joint stiffness There were a total of 50 cases reported for COSENTYX with Joint stiffness for the review period Sep-2021 to Dec-2021. Of the 50 number of cases, 28 cases were reported from the country US, 14 cases were reported from CA, 5 cases were reported from BR, 2 cases were reported from AR, 1 cases were reported from EG. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 21 cases. Of the 50 cases, Information on Dechallenge is available in 9 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Joint stiffness. No changes made
147 911940 2022-05-23 14:02:52 CAERS COSENTYX Dysstasia There were a total of 33 cases reported for COSENTYX with Dysstasia for the review period Sep-2021 to Dec-2021.Concomitant medication(s) have been reported for 32 cases. Conclusion: Based on the available information, COSENTYX has been ruled out for event Dysstasia. No changes made
148 911940 2022-05-23 14:09:28 FAERS COSENTYX Skin lesion There were a total of 100 cases reported for COSENTYX with Skin lesion for the review period Sep-2021 to Dec-2021. Of the 100 number of cases, 57 cases were reported from the country US, 21 cases were reported from BR, 9 cases were reported from CA, 4 cases were reported from CO, 2 cases were reported from AR. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 24 cases. Of the 100 cases, Information on Dechallenge is available in 10 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Skin lesion. No changes made
149 911940 2022-05-23 15:14:24 FAERS COSENTYX Skin plaque There were a total of 129 cases reported for COSENTYX with Skin plaque for the review period Sep-2021 to Dec-2021. Of the 129 number of cases, 90 cases were reported from the country US, 19 cases were reported from CA, 9 cases were reported from CO, 4 cases were reported from AR, 4 cases were reported from BR. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 31 cases. Of the 129 cases, Information on Dechallenge is available in 12 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Skin plaque. No changes made
150 911940 2022-05-23 19:27:51 FAERS COSENTYX Neck pain There were a total of 105 cases reported for COSENTYX with Neck pain for the review period Sep-2021 to Dec-2021. Of the 105 number of cases, 44 cases were reported from the country CA, 34 cases were reported from US, 20 cases were reported from BR, 2 cases were reported from AR, 2 cases were reported from EG. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 63 cases. Of the 105 cases, Information on Dechallenge is available in 18 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Neck pain. No changes made
151 911940 2022-05-25 19:42:10 FAERS COSENTYX Ankylosing spondylitis There were a total of 97 cases reported for COSENTYX with Ankylosing spondylitis for the review period Sep-2021 to Dec-2021. Of the 97 number of cases, 38 cases were reported from the country CA, 24 cases were reported from US, 16 cases were reported from BR, 6 cases were reported from EG, 3 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 57 cases. Of the 97 cases, Information on Dechallenge is available in 19 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Ankylosing spondylitis. No changes made
152 911940 2022-05-25 20:47:35 FAERS COSENTYX Skin plaque There were a total of 129 cases reported for COSENTYX with Skin plaque for the review period Sep-2021 to Dec-2021. Of the 129 number of cases, 90 cases were reported from the country US, 19 cases were reported from CA, 9 cases were reported from CO, 4 cases were reported from AR, 4 cases were reported from BR. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 31 cases. Of the 129 cases, Information on Dechallenge is available in 12 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Skin plaque. No changes made
153 911940 2022-05-31 16:51:36 FAERS COSENTYX Psoriasis There were a total of 1,310 cases reported for COSENTYX with Psoriasis for the review period Sep-2021 to Dec-2021. Of the 1,310 number of cases, 1,021 cases were reported from the country US, 111 cases were reported from CA, 79 cases were reported from BR, 41 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 221 cases. Of the 1,310 cases, Information on Dechallenge is available in 103 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Psoriasis. No changes made
154 911940 2022-06-16 15:23:37 FAERS COSENTYX Ankylosing spondylitis There were a total of 97 cases reported for COSENTYX with Ankylosing spondylitis for the review period Sep-2021 to Dec-2021. Of the 97 number of cases, 38 cases were reported from the country CA, 24 cases were reported from US, 16 cases were reported from BR, 6 cases were reported from EG, 3 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 57 cases. Of the 97 cases, Information on Dechallenge is available in 19 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Ankylosing spondylitis. No changes made
155 911940 2022-06-20 15:17:05 FAERS COSENTYX Ankylosing spondylitis There were a total of 97 cases reported for COSENTYX with Ankylosing spondylitis for the review period Sep-2021 to Dec-2021. Of the 97 number of cases, 38 cases were reported from the country CA, 24 cases were reported from US, 16 cases were reported from BR, 6 cases were reported from EG, 3 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 57 cases. Of the 97 cases, Information on Dechallenge is available in 19 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Ankylosing spondylitis. No changes made
156 911940 2022-06-27 15:10:21 FAERS COSENTYX Drug ineffective There were a total of 1,148 cases reported for COSENTYX with Drug ineffective for the review period Sep-2021 to Dec-2021. Of the 1,148 number of cases, 936 cases were reported from the country US, 104 cases were reported from CA, 54 cases were reported from BR, 13 cases were reported from AR, 12 cases were reported from EG. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 204 cases. Of the 1,148 cases, Information on Dechallenge is available in 82 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Drug ineffective. No changes made
157 911940 2022-07-12 11:00:40 FAERS COSENTYX Arthralgia There were a total of 799 cases reported for COSENTYX with Arthralgia for the review period Sep-2021 to Dec-2021. Of the 799 number of cases, 495 cases were reported from the country US, 119 cases were reported from CA, 96 cases were reported from BR, 31 cases were reported from AR, 19 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 216 cases. Of the 799 cases, Information on Dechallenge is available in 89 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Arthralgia. No changes made
158 911940 2022-07-12 11:08:51 FAERS COSENTYX Product dose omission issue There were a total of 524 cases reported for COSENTYX with Product dose omission issue for the review period Sep-2021 to Dec-2021. Of the 524 number of cases, 411 cases were reported from the country US, 38 cases were reported from BR, 30 cases were reported from CA, 19 cases were reported from GB, 8 cases were reported from AR. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 81 cases. Of the 524 cases, Information on Dechallenge is available in 31 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Product dose omission issue. No changes made
159 911940 2022-07-12 11:47:57 FAERS COSENTYX Pain There were a total of 841 cases reported for COSENTYX with Pain for the review period Sep-2021 to Dec-2021. Of the 841 number of cases, 506 cases were reported from the country US, 128 cases were reported from CA, 124 cases were reported from BR, 31 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 233 cases. Of the 841 cases, Information on Dechallenge is available in 88 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Pain. No changes made
160 911940 2022-07-12 11:55:36 FAERS COSENTYX Pain There were a total of 841 cases reported for COSENTYX with Pain for the review period Sep-2021 to Dec-2021. Of the 841 number of cases, 506 cases were reported from the country US, 128 cases were reported from CA, 124 cases were reported from BR, 31 cases were reported from AR, 12 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 233 cases. Of the 841 cases, Information on Dechallenge is available in 88 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Pain. No changes made
161 911940 2022-08-22 12:01:47 FAERS ABATACEPT No event selected No aggregated narrative No changes made
162 911940 2022-08-22 12:57:00 FAERS ABATACEPT No event selected No aggregated narrative No changes made
163 911940 2022-08-22 12:57:59 FAERS ABATACEPT No event selected No aggregated narrative No changes made
164 911940 2022-08-22 13:00:39 FAERS ABATACEPT Arthralgia There were a total of 52 cases reported for ABATACEPT with Arthralgia for the review period Sep-2021 to Dec-2021. Of the 52 number of cases, 32 cases were reported from the country CA, 6 cases were reported from CL, 6 cases were reported from US, 2 cases were reported from BR, 2 cases were reported from CO. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 34 cases. Of the 52 cases, Information on Dechallenge is available in 17 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, ABATACEPT has been ruled out for event Arthralgia. No changes made
165 911940 2022-08-22 13:03:50 CAERS ORENCIA No event selected No aggregated narrative No changes made
166 911940 2022-08-23 21:39:52 FAERS COSENTYX Malaise There were a total of 217 cases reported for COSENTYX with Malaise for the review period May-2022 to Aug-2022. Of the 217 number of cases, 65 cases were reported from the country US, 55 cases were reported from CA, 32 cases were reported from BR, 20 cases were reported from AR, 16 cases were reported from GB. The information on confounding factor time-to-onset is available in 105 cases. Concomitant medication(s) have been reported for 93 cases. Of the 217 cases, Information on Dechallenge is available in 38 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, COSENTYX has been ruled out for event Malaise. No changes made
167 911940 2022-08-24 11:42:25 FAERS ADALIMUMAB Pulmonary embolism There were a total of 2 cases reported for ADALIMUMAB with Pulmonary embolism for the review period May-2022 to Aug-2022. Of the 2 number of cases, 1 cases were reported from the country CZ, 1 cases were reported from FR. The information on confounding factor time-to-onset is available in 2 cases. Concomitant medication(s) have been reported for 2 cases. Of the 2 cases, Information on Dechallenge is available in 0 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, ADALIMUMAB has been ruled out for event Pulmonary embolism. No changes made
168 911940 2022-08-24 11:45:02 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
169 911940 2022-08-24 11:46:34 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
170 911940 2022-08-24 11:47:48 FAERS ADALIMUMAB Pulmonary tuberculosis There were a total of 3 cases reported for ADALIMUMAB with Pulmonary tuberculosis for the review period Sep-2021 to Dec-2021. Of the 3 number of cases, 2 cases were reported from the country RO, 1 cases were reported from ES. The information on confounding factor time-to-onset is available in 0 cases. Concomitant medication(s) have been reported for 2 cases. Of the 3 cases, Information on Dechallenge is available in 3 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, ADALIMUMAB has been ruled out for event Pulmonary tuberculosis. No changes made
171 911940 2022-08-25 18:23:40 FAERS HUMIRA No event selected No aggregated narrative No changes made
172 911940 2022-08-25 18:26:47 FAERS ABATACEPT No event selected No aggregated narrative No changes made
173 911940 2022-08-25 18:28:34 FAERS ABATACEPT No event selected No aggregated narrative No changes made
174 911940 2022-08-25 18:44:08 FAERS HUMIRA No event selected No aggregated narrative No changes made
175 911940 2022-08-25 18:49:19 FAERS ABATACEPT No event selected No aggregated narrative No changes made
176 911940 2022-08-25 19:00:03 FAERS ABATACEPT No event selected No aggregated narrative No changes made
177 911940 2022-08-25 19:05:17 FAERS HUMIRA No event selected No aggregated narrative No changes made
178 911940 2022-08-25 19:16:26 FAERS abatacept No event selected No aggregated narrative No changes made
179 911940 2022-08-26 11:35:23 FAERS HUMIRA No event selected No aggregated narrative No changes made
180 911940 2022-08-29 12:00:34 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
181 911940 2022-08-29 12:08:34 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
182 911940 2022-08-29 12:18:19 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
183 911940 2022-08-29 12:26:48 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
184 911940 2022-08-29 12:37:25 FAERS ADALIMUMAB Pyrexia There were a total of 23 cases reported for ADALIMUMAB with Pyrexia for the review period May-2022 to Aug-2022. Of the 23 number of cases, 7 cases were reported from the country PT, 4 cases were reported from GB, 3 cases were reported from CA, 3 cases were reported from IT, 2 cases were reported from NL. The information on confounding factor time-to-onset is available in 7 cases. Concomitant medication(s) have been reported for 12 cases. Of the 23 cases, Information on Dechallenge is available in 2 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, ADALIMUMAB has been ruled out for event Pyrexia. No changes made
185 911940 2022-08-29 12:53:33 FAERS ADALIMUMAB Pyrexia There were a total of 23 cases reported for ADALIMUMAB with Pyrexia for the review period May-2022 to Aug-2022. Of the 23 number of cases, 7 cases were reported from the country PT, 4 cases were reported from GB, 3 cases were reported from CA, 3 cases were reported from IT, 2 cases were reported from NL. The information on confounding factor time-to-onset is available in 7 cases. Concomitant medication(s) have been reported for 12 cases. Of the 23 cases, Information on Dechallenge is available in 2 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, ADALIMUMAB has been ruled out for event Pyrexia. No changes made
186 911940 2022-08-29 13:46:38 CAERS ADALIMUMAB Synovitis There were a total of 75 cases reported for ADALIMUMAB with Synovitis for the review period Jan-2022 to Apr-2022.Concomitant medication(s) have been reported for 67 cases. Conclusion: Based on the available information, ADALIMUMAB has been ruled out for event Synovitis. No changes made
187 911940 2022-08-29 13:51:41 CAERS ADALIMUMAB No event selected No aggregated narrative No changes made
188 911940 2022-08-29 15:24:40 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
189 911940 2022-09-07 13:42:31 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
190 911940 2022-09-07 14:00:09 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
191 911940 2022-09-07 14:09:59 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
192 911940 2022-09-07 15:57:06 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
193 911940 2022-09-07 15:57:50 FAERS ADALIMUMAB Drug ineffective There were a total of 57 cases reported for ADALIMUMAB with Drug ineffective for the review period Jan-2022 to Apr-2022. Of the 57 number of cases, 19 cases were reported from the country CA, 8 cases were reported from IT, 6 cases were reported from US, 4 cases were reported from ES, 3 cases were reported from GB. The information on confounding factor time-to-onset is available in 11 cases. Concomitant medication(s) have been reported for 30 cases. Of the 57 cases, Information on Dechallenge is available in 13 cases whereas no information on rechallenge is available. Conclusion: Based on the available information, ADALIMUMAB has been ruled out for event Drug ineffective. No changes made
194 911940 2022-09-07 19:08:07 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
195 911940 2022-09-07 19:13:25 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
196 911940 2022-09-07 19:42:44 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
197 911940 2022-09-07 19:44:50 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
198 911940 2022-09-07 19:48:47 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
199 911940 2022-09-07 19:50:11 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
200 911940 2022-09-07 19:51:54 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
201 911940 2022-09-07 20:52:25 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
202 911940 2022-09-08 01:10:35 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
203 911940 2022-09-08 01:14:05 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
204 911940 2022-09-08 01:16:47 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
205 911940 2022-09-08 01:30:24 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
206 911940 2022-09-08 01:39:41 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
207 911940 2022-09-08 02:18:16 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
208 911940 2022-09-08 02:27:57 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
209 911940 2022-09-08 11:16:56 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
210 911940 2022-09-08 16:07:56 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
211 911940 2022-09-08 16:22:53 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
212 911940 2022-09-08 16:28:07 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
213 911940 2022-09-08 16:51:31 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
214 911940 2022-09-08 17:53:02 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
215 911940 2022-09-08 18:01:04 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
216 911940 2022-09-08 18:03:47 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
217 911940 2022-09-08 18:44:14 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
218 911940 2022-09-08 18:54:31 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
219 911940 2022-09-09 00:02:54 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
220 911940 2022-09-09 01:25:28 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
221 911940 2022-09-09 01:47:43 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
222 911940 2022-09-09 12:13:24 ADALIMUMAB Colon cancer stage II There were a total of 1 cases reported for ADALIMUMAB with Colon cancer stage II for the review period May-2022 - Aug-2022. Of the 1 cases, 1 cases were reported from US. Concomitant medication(s) have been reported for 0 cases.The information on confounding factor time-to-onset is available in 1 cases. No information on Dechallenge is available and no information on Rechallenge is available. Conclusion: Based on the available information, the Adverse Event Colon cancer stage II is ruled out for ADALIMUMAB. No changes made nan
223 911940 2022-09-09 12:16:14 FAERS A Colon cancer stage II There were a total of 1 cases reported for ADALIMUMAB with Colon cancer stage II for the review period May-2022 - Aug-2022. Of the 1 cases, 1 cases were reported from US. Concomitant medication(s) have been reported for 0 cases.The information on confounding factor time-to-onset is available in 1 cases. No information on Dechallenge is available and no information on Rechallenge is available. Conclusion: Based on the available information, the Adverse Event Colon cancer stage II is ruled out for ADALIMUMAB. No changes made
224 911940 2022-09-09 12:43:53 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
225 911940 2022-09-09 12:45:23 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
226 911940 2022-09-09 12:46:44 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
227 911940 2022-09-09 12:48:23 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
228 911940 2022-09-09 12:50:48 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
229 911940 2022-09-09 12:54:08 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
230 911940 2022-09-09 12:56:31 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
231 911940 2022-09-09 12:58:56 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
232 911940 2022-09-09 12:59:09 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
233 911940 2022-09-09 13:04:56 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
234 911940 2022-09-09 13:10:47 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
235 911940 2022-09-09 13:13:19 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
236 911940 2022-09-09 13:18:16 FAERS ADALIMUMAB Arthralgia There were a total of 46 cases reported for ADALIMUMAB with Arthralgia for the review period May-2022 - Aug-2022. Of the 46 cases, 23 cases were reported from CA, 4 cases were reported from AT, 4 cases were reported from CO, 3 cases were reported from HU, 2 cases were reported from NL. Concomitant medication(s) have been reported for 30 cases.The information on confounding factor time-to-onset is available in 11 cases. Of the 46 cases, information on Dechallenge is available in 4 cases and no information on Rechallenge is available. Conclusion: Based on the available information, the Adverse Event Arthralgia is ruled out for ADALIMUMAB. No changes made
237 911940 2022-09-09 13:24:50 FAERS ADALIMUMAB Adenocarcinoma of colon There were a total of 1 cases reported for ADALIMUMAB with Adenocarcinoma of colon for the review period May-2022 - Aug-2022. Of the 1 cases, 1 cases were reported from GB. Concomitant medication(s) have been reported for 1 cases.The information on confounding factor time-to-onset is available in 1 cases. Of the 1 cases, information on Dechallenge is available in 1 cases and no information on Rechallenge is available. Conclusion: Based on the available information, the Adverse Event Adenocarcinoma of colon is ruled out for ADALIMUMAB. No changes made
238 911940 2022-09-09 13:35:16 FAERS ADALIMUMAB Pulmonary fibrosis There were a total of 2 cases reported for ADALIMUMAB with Pulmonary fibrosis for the review period May-2022 - Aug-2022. Of the 2 cases, 1 cases were reported from CA. Concomitant medication(s) have been reported for 1 cases.The information on confounding factor time-to-onset is available in 1 cases. Of the 2 cases, information on Dechallenge is available in 1 cases and no information on Rechallenge is available. Conclusion: Based on the available information, the Adverse Event Pulmonary fibrosis is ruled out for ADALIMUMAB. No changes made
239 911940 2022-09-09 13:39:07 FAERS ADALIMUMAB Colon cancer stage II There were a total of 1 cases reported for ADALIMUMAB with Colon cancer stage II for the review period May-2022 - Aug-2022. Of the 1 cases, 1 cases were reported from US. Concomitant medication(s) have been reported for 0 cases.The information on confounding factor time-to-onset is available in 1 cases. No information on Dechallenge is available and no information on Rechallenge is available. Conclusion: Based on the available information, the Adverse Event Colon cancer stage II is ruled out for ADALIMUMAB. No changes made
240 911940 2022-09-09 13:50:56 FAERS ADALIMUMAB Colon cancer stage II There were a total of 1 cases reported for ADALIMUMAB with Colon cancer stage II for the review period May-2022 - Aug-2022. Of the 1 cases, 1 cases were reported from US. Concomitant medication(s) have been reported for 0 cases.The information on confounding factor time-to-onset is available in 1 cases. No information on Dechallenge is available and no information on Rechallenge is available. Conclusion: Based on the available information, the Adverse Event Colon cancer stage II is ruled out for ADALIMUMAB. No changes made
241 911940 2023-05-09 12:32:31 FAERS ADALIMUMAB No event selected No aggregated narrative No changes made
242 911940 2023-05-09 12:36:36 FAERS ADALIMUMAB Drug ineffective There were a total of 98 cases reported for ADALIMUMAB with Drug ineffective for the review period May-2022 - Aug-2022. Of the 98 cases, 39 cases were reported from CA, 10 cases were reported from IT, 9 cases were reported from ES, 8 cases were reported from GR, 7 cases were reported from FR. Concomitant medication(s) have been reported for 67 cases.The information on confounding factor time-to-onset is available in 19 cases. Of the 98 cases, information on Dechallenge is available in 27 cases and no information on Rechallenge is available. Conclusion: Based on the available information, the Adverse Event Drug ineffective is ruled out for ADALIMUMAB. No changes made
243 911940 2023-05-11 08:35:09 HUMIRA Hip arthroplasty There were a total of 32 cases reported for HUMIRA with Hip arthroplasty for the review period May-2022 - Aug-2022. Of the 32 cases, 19 cases were reported from US, 8 cases were reported from CA, 1 cases were reported from FI. Concomitant medication(s) have been reported for 18 cases.The information on confounding factor time-to-onset is available in 8 cases. Of the 32 cases, information on Dechallenge is available in 7 cases and information on Rechallenge is available in 3 cases. Conclusion: Based on the available information, the Adverse Event Hip arthroplasty is ruled out for HUMIRA. No changes made nan
244 911940 2023-05-17 12:37:56 ABATACEPT Swelling There were a total of 5 cases reported for ABATACEPT with Swelling for the review period May-2022 - Aug-2022. Of the 5 cases, 5 cases were reported from CA, 1 cases were reported from CO, 1 cases were reported from GB, 1 cases were reported from JP. Concomitant medication(s) have been reported for 6 cases.The information on confounding factor time-to-onset is available in 3 cases. Of the 5 cases, information on Dechallenge is available in 2 cases and no information on Rechallenge is available. Conclusion: Based on the available information, the Adverse Event Swelling is ruled out for ABATACEPT. No changes made nan
245 911940 2023-05-17 14:11:23 FAERS ADALIMUMAB Blood iron decreased There were a total of 6 cases reported for ADALIMUMAB with Blood iron decreased for the review period May-2022 - Aug-2022. Of the 6 cases, 6 cases were reported from RO. Concomitant medication(s) have been reported for 6 cases.The information on confounding factor time-to-onset is available in 1 cases. Of the 6 cases, information on Dechallenge is available in 6 cases and no information on Rechallenge is available. Conclusion: Based on the available information, the Adverse Event Blood iron decreased is ruled out for ADALIMUMAB. No changes made
246 911940 2023-05-17 15:17:01 FAERS ADALIMUMAB Synovitis There were a total of 23 cases reported for ADALIMUMAB with Synovitis for the review period May-2022 - Aug-2022. Of the 23 cases, 12 cases were reported from CA, 2 cases were reported from AT, 2 cases were reported from CH, 1 cases were reported from FI, 1 cases were reported from RO. Concomitant medication(s) have been reported for 17 cases.The information on confounding factor time-to-onset is available in 4 cases. Of the 23 cases, information on Dechallenge is available in 4 cases and no information on Rechallenge is available. Conclusion: Based on the available information, the Adverse Event Synovitis is ruled out for ADALIMUMAB. No changes made
247 911940 2023-06-05 03:44:43 FAERS ADALIMUMAB Colitis ulcerative There were a total of 24 cases reported for ADALIMUMAB with Colitis ulcerative for the review period May-2022 - Aug-2022. Of the 24 cases, 13 cases were reported from RO, 2 cases were reported from CA, 2 cases were reported from FR, 2 cases were reported from PT, 1 cases were reported from ES. Concomitant medication(s) have been reported for 13 cases.The information on confounding factor time-to-onset is available in 6 cases. Of the 24 cases, information on Dechallenge is available in 7 cases and no information on Rechallenge is available. Conclusion: The Adverse Event Colitis ulcerative is ruled out for ADALIMUMAB as Colitis ulcerative is an Indication for which ADALIMUMAB is consumed. No changes made
248 911940 2023-06-05 03:46:45 FAERS ADALIMUMAB Arthralgia There were a total of 46 cases reported for ADALIMUMAB with Arthralgia for the review period May-2022 - Aug-2022. Of the 46 cases, 23 cases were reported from CA, 4 cases were reported from AT, 4 cases were reported from CO, 3 cases were reported from HU, 2 cases were reported from NL. Concomitant medication(s) have been reported for 30 cases.The information on confounding factor time-to-onset is available in 11 cases. Of the 46 cases, information on Dechallenge is available in 4 cases and no information on Rechallenge is available. Conclusion: Based on the available information, the Adverse Event Arthralgia is ruled out for ADALIMUMAB. No changes made
249 911940 2023-06-05 03:50:36 FAERS ADALIMUMAB Drug ineffective There were a total of 98 cases reported for ADALIMUMAB with Drug ineffective for the review period May-2022 - Aug-2022. Of the 98 cases, 39 cases were reported from CA, 10 cases were reported from IT, 9 cases were reported from ES, 8 cases were reported from GR, 7 cases were reported from FR. Concomitant medication(s) have been reported for 67 cases.The information on confounding factor time-to-onset is available in 19 cases. Of the 98 cases, information on Dechallenge is available in 27 cases and no information on Rechallenge is available. Conclusion: Based on the available information, the Adverse Event Drug ineffective is ruled out for ADALIMUMAB. No changes made
250 911940 2023-06-05 06:14:16 FAERS ADALIMUMAB Colitis ulcerative There were a total of 24 cases reported for ADALIMUMAB with Colitis ulcerative for the review period May-2022 - Aug-2022. Of the 24 cases, 13 cases were reported from RO, 2 cases were reported from CA, 2 cases were reported from FR, 2 cases were reported from PT, 1 cases were reported from ES. Concomitant medication(s) have been reported for 13 cases.The information on confounding factor time-to-onset is available in 6 cases. Of the 24 cases, information on Dechallenge is available in 7 cases and no information on Rechallenge is available. Conclusion: The Adverse Event Colitis ulcerative is ruled out for ADALIMUMAB as Colitis ulcerative is an Indication for which ADALIMUMAB is consumed. No changes made
251 911940 2023-07-20 04:58:17 FAERS S Metastases to liver There were a total of 8 cases reported for SANDOSTATIN with Metastases to liver for the review period May-2022 - Aug-2022. Of the 8 cases, 24 cases were reported from CA, 2 cases were reported from CO, 1 cases were reported from AR, 1 cases were reported from MX. Concomitant medication(s) have been reported for 22 cases.The information on confounding factor time-to-onset is available in 29 cases. Of the 8 cases, information on Dechallenge is available in 9 cases and no information on Rechallenge is available. Conclusion: Based on the available information, the Adverse Event Metastases to liver is ruled out for SANDOSTATIN. No changes made